Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus

被引：31

作者：

Garnock-Jones, Karly P. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2017年 / 77卷 / 03期

关键词：

SAXAGLIPTIN PLUS DAPAGLIFLOZIN; DOUBLE-BLIND TRIAL; ADD-ON; COMBINATION THERAPY; TRIPLE THERAPY; BLADDER-CANCER; INHIBITOR PLUS; METFORMIN; MANAGEMENT; EFFICACY;

D O I：

10.1007/s40265-017-0697-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern (R)) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of saxagliptin/dapagliflozin provides inadequate glycaemic control, or when the patient is already being treated with the free combination of saxagliptin + dapagliflozin. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of saxagliptin/dapagliflozin in this indication. The agents have complementary mechanisms of action, and saxagliptin/dapagliflozin fixed-dose combination tablets are bioequivalent to free combination of saxagliptin + dapagliflozin. In three phase III trials, saxagliptin + dapagliflozin + metformin was more effective at providing glycaemic control than saxagliptin + metformin or dapagliflozin + metformin in previously treated patients with T2DM and inadequate glycaemic control on metformin monotherapy or metformin plus one of the monocomponents. The combination is associated with decreased bodyweight and a low risk of hypoglycaemia. As the first dipeptidyl peptidase-4 (DPP-4) inhibitor/sodium-glucose co-transporter (SGLT2) inhibitor fixed-dose combination available in the EU for glycaemic control in patients with T2DM, saxagliptin/dapagliflozin is a useful new option in this setting.

引用

页码：319 / 330

页数：12

共 28 条

[1] Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes? [J].

Abdul-Ghani, Muhammad .

DIABETES CARE, 2015, 38 (03) :373-375

[2]

[Anonymous], 2012, CPMPEWP108000

[3]

[Anonymous], 2012, Global Guideline for Type 2 diabetes

[4] Combine and conquer: advantages and disadvantages offixed-dose combination therapy [J].

Bell, D. S. H. .

DIABETES OBESITY & METABOLISM, 2013, 15 (04) :291-300

[5] Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin [J].

Boulton, David W. ;

Kasichayanula, Sreeneeranj ;

Keung, Chi Fung ;

Arnold, Mark E. ;

Christopher, Lisa J. ;

Xu, Xiaohui ;

LaCreta, Frank .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (03) :763-768

[6] Saxagliptin: A Review in Type 2 Diabetes [J].

Dhillon, Sohita .

DRUGS, 2015, 75 (15) :1783-1796

[7]

Ekholm E, 2015, DIABETOLOGIA, V58, pS349

[8]

European Medicines Agency, 2016, EMEAHC0040570000

[9]

European Medicines Agency, 2016, QTEM SAX HYDR DAP PR

[10] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

← 1 2 3 →